Protocol Ledger

NCT04414475 · Phase II · RECRUITING

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Interventional Phase II clinical trial protocol NCT04414475 sponsored by Karyopharm Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-01 Enrollment: 127 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04414475
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)127 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04414475
Protocol FieldVerified Registry Value
NCT IdentifierNCT04414475
Consolidated Lead SponsorKaryopharm Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment127 participants (ESTIMATED)
Registered Start Date2020-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04414475
Hospital Research SiteLocationSite Profile
Bnai Zion Medical CenterHaifa, IsraelOpen Hospital Dossier ->
Rambam Health Care CampusHaifa, IsraelOpen Hospital Dossier ->
Shaare Zedek Medical CenterJerusalem, IsraelOpen Hospital Dossier ->
Hadassah Medical CenterJerusalem, IsraelOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI